Liposomes: The science and the regulatory landscape

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 20, Issue , 2015, Pages 77-106

  Crommelin, Daan J A ^a   Metselaar, Josbert M ^b   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Enceladus Pharmaceuticals BV   (Netherlands)

Author keywords

Ambisome ; Caelyx ; Doxil ; EMA; Enhanced Permeability and Retention (EPR); FDA; Formulation; Generic follow on liposomes; Liposomes; Manufacturing

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BUPIVACAINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; MACROGOL; MIFAMURTIDE; MORPHINE SULFATE; OXALIPLATIN; PLASMID DNA; VERTEPORFIN; VINCRISTINE SULFATE;

ALLERGIC REACTION; ARTICLE; BIOEQUIVALENCE; BREAST CANCER; DRUG DESIGN; DRUG PENETRATION; ESOPHAGEAL ADENOCARCINOMA; GLIOBLASTOMA; LIPID BILAYER; LIPOSOMAL DELIVERY; OPSONIZATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PRIORITY JOURNAL; QUALITY BY DESIGN; SMALL ANGLE SCATTERING; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; WORLD HEALTH ORGANIZATION; ZETA POTENTIAL;

EID: 85079135850     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-16241-6_3     Document Type: Article

References (74)

1. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36-48
2. Allen TN, Hansen CB (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133-141
3. Amphonex (2014) http://www.bharatserums.com/product/neurology/AMPHONEX%2050mg%20 %28Lyo%29%20Pack%20Insert%20for%20Domestic_2013_04_06_07_45_20_893.pdf
4. Arshinova OY, Sanarova EV, Lantsova AV, Oborotova NA (2012) Drug synthesis methods and manufacturing technology: lyophilization of liposomal drug forms. Pharm Chem J 46:228-233
5. Bae YH, Park K (2011) Drug delivery to tumors: myths, reality and possibility. J Controlled Release 153:198-205
6. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Genovese GO, Milani B, Gaspan S, Potet J, Chappuis F (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17:493-510
7. Barenholz Y (2012) Doxil®-The first FDA-approved nano-drug: lessons learned. J Control Release 160:117-134
8. Barenholz Y, Crommelin DJA (1994) Liposomes as pharmaceutical dosage forms. In: Swarbrick J, Boylan JC (eds) Encyclopedia of pharmaceutical technology, vol 9. Marcel Dekker, Inc, NY, pp 1-39
9. Bhardwaj U, Burgess DJ (2010) A novel USP apparatus 4 based release testing method for dispersed systems. Intl J Pharm 388:287-294
10. Carstens MG, Romberg B, Oussoren C, Storm G (2007) Observations on the disappearance of the stealth property of PEGylated liposomes: effects of lipid dose and dosing frequency. In: Gregoriadis G (ed) Liposome technology, vol III, 3rd edn. CRC Press, Boca Raton pp 79-94
11. CBG-MEB (2012) http://www.cbg-meb.nl/NR/rdonlyres/E2508764-9FC9-4C59-BE29-B02DB4 361E91/0/1208DHPCDepocyteEN.pdf. Accessed 26 April 2015
12. CHMP assessment report Doxorubicin SUN EMA (2011) http://www.ema.europa.eu/docs/ en_GB/document_library/Application_withdrawal_assessment_report/human/002049/ WC500112957.pdf. Accessed 26 April 2015
13. Chassu D, Holt K, Chader GJ (2013) Nanoparticle-based therapeutics, an overview. In: Chassu D, Chader GJ. (eds) Ocular drug delivery systems: barriers and application of nanoparticulate systems. CRC Press, Boca Raton, pp 3-16
14. Chonn A, Semple SC, Cullis PR (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267:18759-18765
15. Crommelin DJA, Florence AT (2013) Towards more effective advanced drug delivery systems. Int J Pharm 454:496-511
16. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, Van der Meer JW, Corstens FHM, Boerman OC (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071-1079
17. Druckmann S, Gabizon A, Barenholz Y (1989) Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim Biophys Acta 980:381-384
18. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97:4696-4740
19. EMA ICH, Topic M 4 (2004) Common technical document for the registration of pharmaceuticals for human use -organisation CTD. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500002721.pdf. Accessed 26 April 2015
20. EMA Questions and answers on the supply situation of Caelyx (2012) http://www.ema.europa.eu/ docs/en_GB/document_library/Medicine_QA/2013/04/WC500142510.pdf. Accessed 26 April 2015
21. EMA Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product (2013) http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2013/03/WC500140351.pdf. Accessed 26 April 2015
22. EMA Summary of product characteristics Myocet (EPAR) (2010) http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR__Product_Information/human/000297/WC500031811. pdf. Accessed 26 April 2015
23. EMA Summary of product characteristics Caelyx (EPAR) (2014) http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR__Product_Information/human/000089/WC500020180.pdf. Accessed 26 April 2015
24. EMA Volume 2B Notice to applicants medicinal products for human use (2006) http://ec.europa. eu/health/files/eudralex/vol-2/b/update_200805/ctd_05-2008_en.pdf. Accessed 26 April 2015
25. EMEA Scientific discussion Caelyx (2005) http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Scientific_Discussion/human/000089/WC500020175.pdf. Accessed 26 April 2015
26. FDA (2002) Guidance for Industry: Liposome Drug Products http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf. Accessed 26 April 2015
27. FDA Ben Venue Laboratories-Voluntary Shutdown (2011) http://www.fda.gov/Drugs/DrugSafety/ ucm281782.htm. Accessed 26 April 2015
28. FDA Draft Guidance on Doxorubicin Hydrochloride (2010) http://www.fda.gov/downloads/ Drugs/…/Guidances/UCM199635.pdf. Accessed 26 April 2015
29. FDA Grants (2014) http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-016.html. Accessed 26 April 2015
30. Fenske DB, Maurer N, Cullis PR (2003) Encapsulation of weakly-basic drugs, antisense oligonucleotides and plasmid DNA within large unilamellar vesicles for drug delivery applications. In: Torchilin VP, Weissig V (eds) Liposomes, a practical approach, second edition. Oxford University, Oxford, pp 173-180
31. Fierce Pharma Manufacturing (2013) http://www.fiercepharmamanufacturing.com/story/gileadrecalls- 20-batches-Ambisome-due-possible-contamination/2013-06-19. Accessed 26 April 2015
32. Fungisome (2014) http://www.lifecareinnovations.com/. Accessed 26 April 2015
33. Gaspani S, Milani B (2013) Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx. GaBI J 2:60-62
34. Gaspar R (2010) Therapeutic products: regulating drugs and medical devices. In: Hodge GA et al. (eds) International handbook on regulating nanotechnologies. Edward Elgar, Cheltenham, pp 291-320
35. Gregoriadis G (2006) Liposome technology, vol I, II and III, 3rd Revised edn. Taylor & Francis Inc, Hoboken
36. Griese N, Blaschke G, Boos J, Hempel G (2002) Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis. J Chromatogr A 979:379-388
37. Grit M, Zuidam N, Crommelin DJAC (1993) Analysis and hydrolyis kinetics of phospholipids in liposome dispersions. In: Gregoriadis G (ed) Liposome technology, vol III, 2nd edn. CRC Press, Boca Raton, pp 455-485
38. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RM, Stewart JSW (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243-254
39. Jiang W, Lionberger R, Yu LX (2011) In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3:333-344
40. Kim HS, Wainer IW (2010) Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence. J Pharm Biomed Anal 52:372-376
41. Kraft JC, Freeling JP, Wang Z, Ho RJY (2013) Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103:1520-6017
42. Kshirsagar NA, Pandya SK, Kirodian BG, Sanath S (2005) Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 51:5-15
43. Lammers T, Rizzo LY, Storm G, Kiessling F (2012) Personalized nanomedicine. Clin Cancer Res 18:4889-4894
44. Lasch J, Weissing V, Brandi M (2003) Preparation of liposomes. In: Torchilin VP, Weissing V (eds) Liposomes, a practical approach, 2nd edn. Oxford University Press, Oxford, pp 267-286
45. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G (2001) Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298:707-712
46. Mamidi RNVS, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC (2010) Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother Pharmacol 66:1173-1184
47. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle Th, Bubendorf L, Hilker C, Deuster S, Herrmann R Rochlitz C (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicinloaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 13:1234-1241
48. Mayer LD, St-Onge G (1995) Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232:149-157
49. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478
50. Nag A, Mitra G, Ghosh PC (1997) A colorimetric estimation of polyethyleneglycol-conjugated phospholipid in stealth liposomes. Anal Biochem 250:35-43
51. NANOMEDICINE 2020: Contribution of Nanomedicine to Horizon 2020 (2013) http://www.etpnanomedicine. eu/public/press-documents/publications/etpn-publications/etpn-white-paper- H2020
52. Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT (2008) Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin b products. Antimicrob Agents Chemother 52:259-268
53. Oussoren C, Storm G (1999) Effect of repeated i.v. administration on the circulation kinetics of poly(ethyleneglycol)-liposomes in rats. J Liposome Res 9:349-355
54. Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7:7442-7447
55. Storm G, Belliot SO, Daemen T, Lasic DD (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Delivery Rev 17:31-48
56. Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 216:106-121
57. Szebeni J, Muggi F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Delivery Rev 63:1020-1030
58. Taiwan Trade Center, Toronto (2013) http://toronto.taiwantrade.com.tw/news/detail. jsp?id=12817&lang=En-US_US. Accessed 26 April 2015
59. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD (1990) Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188:65-71
60. TLC (2013) http://www.tlcbio.com/upload/media/investor/%E6%B3%95%E8%AA%AA%E6% 9C%83%E7%B0%A1%E5%A0%B1/Company%20Yearly%20Update%20for%20201403_ v5.pdf. Accessed 26 April 2015
61. van den Hoven JM (2012) Liposomal glucocorticoids: pharmaceutical, preclinical and clinical aspects, Thesis Utrecht University. http://dspace.library.uu.nl/handle/1874/256300
62. van der Meel R, Vehmeijer LJC, Kok RJ, Storm G, van Gaal EVB (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65:1284-1298
63. van Winden EC (2003) Freeze-drying of liposomes: theory and practice. Methods Enzymol 367:99-110
64. Varga Z, Wacha A, Vainio U, Gummel J, Bóta A (2012) Characterization of the PEG layer of sterically stabilized liposomes: a SAXS study. Chem Phys Lipids 165:387-392
65. Venditto VJ, Szoka FC (2013) Cancer nanomedicines: so many papers and so few drugs! Adv Drug Delivery Rev 65:80-88
66. Vernooij EA, Gentry CA, Herron JN, Crommelin DJ, Kettenes-van den Bosch JJ (1999) 1H NMR quantification of poly(ethylene glycol)-phospatidylethanolamine in phospholid mixtures. Pharm Res 16:1658-1661
67. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171- 199
68. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ, Papahadjopoulos D (1992) Versatility in lipid composition showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105:193-200
69. Xu X, Khan MA, Burgess DJ (2011) Formulation, processing design and risk assessment. Int J Pharm 419:52-59
70. Xu X, Khan MA, Burgess DJ (2012a) A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423:543-553
71. Xu X, Costa AP, Khan MA, Burgess DJ (2012b) Application of quality by design to formulation and processing of protein liposomes. Int J Pharm 434:349-359
72. Xu X, Khan MA, Burgess DJ (2012c) A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int J Pharm 426:211-218
73. Yoshino K, Taguchi K, Mochizuki M, Nozawa S, Kasukawa H, Kono K (2012) Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes. Colloids Surf A Physicochem Eng Aspects 397:73-79
74. Zuidam NJ, Van Winden E, De Vrueh R, Crommelin DJA (2003) Stability, storage, and sterilization of liposomes. In: Torchilin VP, Weissing V (eds) Liposomes, a practical approach, 2nd edn. Oxford University Press, Oxford, pp 149-165